Michele Guida

5.7k total citations
146 papers, 3.2k citations indexed

About

Michele Guida is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michele Guida has authored 146 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Oncology, 58 papers in Molecular Biology and 33 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michele Guida's work include Melanoma and MAPK Pathways (48 papers), Cancer Immunotherapy and Biomarkers (38 papers) and CAR-T cell therapy research (29 papers). Michele Guida is often cited by papers focused on Melanoma and MAPK Pathways (48 papers), Cancer Immunotherapy and Biomarkers (38 papers) and CAR-T cell therapy research (29 papers). Michele Guida collaborates with scholars based in Italy, United States and France. Michele Guida's co-authors include Sabino Strippoli, Vanna Chiarion‐Sileni, Laura Ridolfi, Amalia Azzariti, Paolo A. Ascierto, David M. Berman, Aviram Nissan, Henry Gómez, Henrik Schmidt and Steinar Aamdal and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Michele Guida

141 papers receiving 3.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michele Guida Italy	27	2.2k	1.2k	892	691	350	146	3.2k
Sergio Palomo‐Ponce Spain	8	2.3k 1.1×	1.9k 1.7×	854 1.0×	534 0.8×	850 2.4×	10	3.9k
Iván Márquez‐Rodas Spain	25	3.0k 1.4×	1.3k 1.2×	1.2k 1.4×	778 1.1×	380 1.1×	120	4.1k
Robert D. Loberg United States	34	2.1k 1.0×	1.6k 1.4×	1.0k 1.2×	920 1.3×	832 2.4×	59	4.1k
Andreas Pircher Austria	27	1.5k 0.7×	1.7k 1.5×	871 1.0×	855 1.2×	931 2.7×	103	3.4k
Cristina Nadal Spain	17	2.3k 1.1×	2.2k 1.9×	475 0.5×	726 1.1×	1.3k 3.6×	42	4.3k
Vijaya Ramachandran United States	27	2.1k 1.0×	2.0k 1.7×	768 0.9×	406 0.6×	941 2.7×	46	4.0k
Julienne L. Carstens United States	12	1.9k 0.9×	1.7k 1.5×	602 0.7×	392 0.6×	896 2.6×	16	3.4k
Jair Bar Israel	28	1.5k 0.7×	832 0.7×	349 0.4×	992 1.4×	504 1.4×	152	2.6k
José A. López-Martín Spain	28	1.3k 0.6×	824 0.7×	243 0.3×	601 0.9×	352 1.0×	123	2.4k
Luis de la Cruz‐Merino Spain	26	2.6k 1.2×	1.9k 1.7×	812 0.9×	703 1.0×	541 1.5×	175	4.0k

Countries citing papers authored by Michele Guida

Since Specialization

Citations

This map shows the geographic impact of Michele Guida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michele Guida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michele Guida more than expected).

Fields of papers citing papers by Michele Guida

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michele Guida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michele Guida. The network helps show where Michele Guida may publish in the future.

Co-authorship network of co-authors of Michele Guida

This figure shows the co-authorship network connecting the top 25 collaborators of Michele Guida. A scholar is included among the top collaborators of Michele Guida based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michele Guida. Michele Guida is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Grignani, Giovanni, Piotr Rutkowski, Célèste Lebbé, et al.. (2025). Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201). Journal for ImmunoTherapy of Cancer. 13(8). e012478–e012478. 2 indexed citations

Azzariti, Amalia, Simona De Summa, Ivana De Risi, et al.. (2025). Developing a risk score using liquid biopsy biomarkers for selecting Immunotherapy responders and stratifying disease progression risk in metastatic melanoma patients. Journal of Experimental & Clinical Cancer Research. 44(1). 40–40. 2 indexed citations

Grabbe, Stephan, Michele Guida, Janet L. Markman, et al.. (2025). 1605MO Primary results from a randomized phase II trial of BNT111 in combination with cemiplimab with calibrator monotherapy arms in anti-PD-(L)1 relapsed/refractory melanoma. Annals of Oncology. 36. S885–S886.

Ascierto, Paolo A., Pietro Quaglino, Francesco Spagnolo, et al.. (2024). Combination or sequence of vemurafenib, cobimetinib, and atezolizumab in high-risk, resectable melanoma (NEO-TIM): Primary results.. Journal of Clinical Oncology. 42(17_suppl). LBA9513–LBA9513. 2 indexed citations

Giacomo, Anna Maria Di, Michele Del Vecchio, Pier Francesco Ferrucci, et al.. (2023). 1084MO Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial. Annals of Oncology. 34. S653–S654. 2 indexed citations

Grignani, Giovanni, Piotr Rutkowski, Célèste Lebbé, et al.. (2023). 1146P Updated results from POD1UM-201: A phase II study of retifanlimab in patients with advanced or metastatic Merkel cell carcinoma (MCC). Annals of Oncology. 34. S686–S686. 10 indexed citations

Cannella, L., Rosa Della Monica, Bruno Vincenzi, et al.. (2023). The Impact of O6-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation on the Outcomes of Patients with Leiomyosarcoma Treated with Dacarbazine. Cells. 12(12). 1635–1635. 3 indexed citations

Sergi, Maria Chiara, Michele Guida, Paolo Trerotoli, et al.. (2023). Melanoma Brain Metastases: A Retrospective Analysis of Prognostic Factors and Efficacy of Multimodal Therapies. Cancers. 15(5). 1542–1542. 9 indexed citations

Giacomo, Anna Maria Di, Vanna Chiarion‐Sileni, Michele Del Vecchio, et al.. (2021). Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases. Clinical Cancer Research. 27(17). 4737–4745. 41 indexed citations

10.

Aglietta, Massimo, Vanna Chiarion‐Sileni, Paolo Fava, et al.. (2021). Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy). Targeted Oncology. 16(6). 789–799. 5 indexed citations

11.

Guida, Michele, Nicola Bartolomeo, Pietro Quaglino, et al.. (2021). No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study. Cancers. 13(3). 475–475. 19 indexed citations

12.

Ascierto, P.A., Mario Mandalà, Pier Francesco Ferrucci, et al.. (2021). LBA40 SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study. Annals of Oncology. 32. S1316–S1317. 18 indexed citations

13.

Saponara, Maristella, Laura Pala, Fabio Conforti, et al.. (2020). Patients with locally advanced and metastatic cutaneous squamous cell carcinoma treated with immunotherapy in the era of COVID-19: stop or go? Data from five Italian referral cancer centers. Therapeutic Advances in Medical Oncology. 12. 3863592042–3863592042. 4 indexed citations

14.

Constantinidou, Anastasia, Nicolas Sauvé, Silvia Stacchiotti, et al.. (2020). Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. ESMO Open. 5(4). e000787–e000787. 26 indexed citations

15.

Giacomo, Anna Maria Di, Michele Del Vecchio, Pier Francesco Ferrucci, et al.. (2020). 1081MO Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial. Annals of Oncology. 31. S734–S734. 3 indexed citations

16.

Maida, Immacolata, Paola Zanna, Stefania Guida, et al.. (2019). Translational control mechanisms in cutaneous malignant melanoma: the role of eIF2α. Journal of Translational Medicine. 17(1). 20–20. 10 indexed citations

17.

Cabula, Carlo, L Campana, Riccardo Bussone, et al.. (2015). Electrochemotherapy in the Treatment of Cutaneous Metastases from Breast Cancer: A Multicenter Cohort Analysis. Annals of Surgical Oncology. 22(S3). 442–450. 46 indexed citations

18.

Niro, Alfredo, Sabino Strippoli, Giovanni Alessio, et al.. (2015). Ocular Toxicity in Metastatic Melanoma Patients Treated With Mitogen-Activated Protein Kinase Kinase Inhibitors: A Case Series. American Journal of Ophthalmology. 160(5). 959–967.e1. 32 indexed citations

19.

Maio, Michele, Paolo A. Ascierto, Alessandro Testori, et al.. (2012). The cost of unresectable stage III or stage IV melanoma in Italy. Journal of Experimental & Clinical Cancer Research. 31(1). 91–91. 26 indexed citations

20.

Ridolfi, Ruggero, Antonella Romanini, Vanna Chiarion‐Sileni, et al.. (2004). Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup. Melanoma Research. 14(4). 295–299. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact